HDAC9 and non-small cell lung carcinoma: Preclinical studies in peripheral blood mononuclear cells from patients with NSCLC revealed a significant reduction in regulatory T cell (Treg) proportions coincident with CD8+ and CD4+ T cell activation upon treatment with ricolinostat compared with the class I HDAC inhibitor entinostat (24).